Published in Cancer Res on April 01, 1992
Mitochondria as a critical target of the chemotheraputic agent cisplatin in head and neck cancer. J Bioenerg Biomembr (2007) 1.12
Mechanisms of resistance to photodynamic therapy. Curr Med Chem (2011) 0.96
Mitochondrial contributions to cancer cell physiology: redox balance, cell cycle, and drug resistance. J Bioenerg Biomembr (1997) 0.92
Estrogen Enhances the Expression of the Multidrug Transporter Gene ABCG2-Increasing Drug Resistance of Breast Cancer Cells through Estrogen Receptors. Int J Mol Sci (2017) 0.75
Abrogation of cisplatin-induced programmed cell death in human breast cancer cells by epidermal growth factor antisense RNA. J Natl Cancer Inst (1997) 1.88
Endogenous complement C3 synthesis in immune complex nephritis. Lancet (1993) 1.57
Reductive activation of mitomycin C and mitomycin C metabolites catalyzed by NADPH-cytochrome P-450 reductase and xanthine oxidase. J Biol Chem (1984) 1.54
Differential potentiation of alkylating and platinating agent cytotoxicity in human ovarian carcinoma cells by glutathione depletion. Cancer Res (1985) 1.30
Free proximal trisomy 21 without the Down syndrome. Clin Genet (1987) 1.19
Modulation of cis-diamminedichloroplatinum(II) accumulation and sensitivity by forskolin and 3-isobutyl-1-methylxanthine in sensitive and resistant human ovarian carcinoma cells. Int J Cancer (1991) 1.18
Cancer incidence in the industrial corridor: an update. J La State Med Soc (1998) 1.17
Phase I/pharmacokinetic study of intraperitoneal cisplatin and etoposide. Cancer Res (1987) 1.16
Skin tumours posttransplantation: a retrospective analysis of 28 years' experience at a single centre. Transplant Proc (1997) 1.14
Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother Pharmacol (1987) 1.13
Renal disease and use of topical non-steroidal anti-inflammatory drugs. BMJ (1994) 1.10
Increased sensitivity to cis-diamminedichloroplatinum(II) in human ovarian carcinoma cells in response to treatment with 12-O-tetradecanoylphorbol 13-acetate. J Biol Chem (1990) 1.10
Outcome of transplantation of non-heart-beating donor kidneys. Lancet (1995) 1.09
Immunohistochemical staining for glutathione S-transferase predicts response to platinum-based chemotherapy in head and neck cancer. Clin Cancer Res (1996) 1.05
Epidermal growth factor regulates the in vitro sensitivity of human ovarian carcinoma cells to cisplatin. J Clin Invest (1990) 1.03
Short-term cis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Chemother Pharmacol (1990) 1.01
The adducted thumbs syndrome. An autosomal recessive disease with arthrogryposis, dysmyelination, craniostenosis, and cleft palate. Clin Genet (1971) 0.97
Facile and definitive determination of human adriamycin and daunoribicin metabolites by high-pressure liquid chromatography. Drug Metab Dispos (1980) 0.96
Hypermethylation of human DNA sequences in embryonal carcinoma cells and somatic tissues but not in sperm. Nucleic Acids Res (1987) 0.96
Effect of intracellular chloride on the cellular pharmacodynamics of cis-diamminedichloroplatinum(II). Drug Metab Dispos (1995) 0.91
Renal failure in a patient with chronic myelomonocytic leukaemia. Nephrol Dial Transplant (1997) 0.91
Regulatory considerations for preclinical development of anticancer drugs. Cancer Chemother Pharmacol (1998) 0.91
High-dose cisplatin with sodium thiosulfate protection. J Clin Oncol (1985) 0.90
Expression of the c-Ha-ras oncogene in mouse NIH 3T3 cells induces resistance to cisplatin. Cancer Res (1991) 0.89
Pharmacokinetics of 5-fluorouracil during hyperthermic pelvic isolation-perfusion. J Clin Oncol (1985) 0.88
Comparison of lipid content, surface membrane fluidity, and temperature dependence of cis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Anticancer Res (1989) 0.88
Association between expression of glutathione-associated enzymes and response to platinum-based chemotherapy in head and neck cancer. Chem Biol Interact (1998) 0.88
Predictive value of preclinical toxicology studies for platinum anticancer drugs. Clin Cancer Res (1999) 0.87
Safety and efficacy of TNFalpha blockade in relapsing vasculitis. Ann Rheum Dis (2002) 0.87
NSAIDS in the postoperative period. Many factors threaten renal function. BMJ (1993) 0.87
Decreased cisplatin/DNA adduct formation is associated with cisplatin resistance in human head and neck cancer cell lines. Cancer Chemother Pharmacol (2000) 0.86
Glutathione depletion reverses cisplatin resistance in murine L1210 leukemia cells. Cancer Lett (1987) 0.86
Modulation of cis-diamminedichloroplatinum (II) accumulation and cytotoxicity by spermine in sensitive and resistant human ovarian carcinoma cells. Eur J Cancer (1997) 0.84
Differential sensitization of human ovarian carcinoma and mouse L1210 cells to cisplatin and melphalan by glutathione depletion. Mol Pharmacol (1986) 0.83
Guidelines for liver transplantation for patients with non-alcoholic steatohepatitis. Gut (2012) 0.82
Inhibitors of intracellular pH regulation induce cisplatin resistance in EMT6 mouse mammary tumor cells. Oncol Res (1995) 0.82
Is there a 'cancer corridor' in Louisiana? J La State Med Soc (1996) 0.81
Ring chromosome 12. Am J Med Genet (1988) 0.80
Racial variation in dosage requirements of tacrolimus. Lancet (1996) 0.80
The effect of DNA polymerase inhibitors on the cytotoxicity of cisplatin in human ovarian carcinoma cells. Cancer Commun (1990) 0.80
Cancer of the colon and rectum in Louisiana. J La State Med Soc (1999) 0.80
Poorer graft survival in ethnic minorities: results from a multi-centre UK study of kidney transplant outcomes. Clin Nephrol (2011) 0.80
Nocturnal body temperature regulation in man: a rationale for sweating in sleep. J Appl Physiol (1966) 0.79
Glutathione content but not gamma glutamyl cysteine synthetase mRNA expression predicts cisplatin resistance in head and neck cancer cell lines. Cancer Chemother Pharmacol (1997) 0.79
Effect of topoisomerase modulators on cisplatin cytotoxicity in human ovarian carcinoma cells. Eur J Cancer (1990) 0.78
A high-performance liquid chromatographic assay with improved selectivity for cisplatin and active platinum (II) complexes in plasma ultrafiltrate. Anal Biochem (1984) 0.78
Rapid determination of C-reactive protein levels: semiquantitative versus quantitative. J Pediatr (1987) 0.78
Kidney donation after paracetamol overdose. BMJ (1993) 0.78
Pharmacokinetic study of intraperitoneal streptozotocin. Clin Invest Med (1992) 0.78
Highlights of cancer incidence in Louisiana, 1988-1992. J La State Med Soc (1997) 0.78
A regulatory view of the Medicines Act in the United Kingdom. J Clin Pharmacol (1984) 0.78
Phase II evaluation and plasma pharmacokinetics of high-dose intravenous 6-thioguanine in patients with colorectal carcinoma. Cancer Chemother Pharmacol (1982) 0.78
Cytomegalovirus infection and abdominal pain with mycophenolate mofetil: is there a link? Drug Saf (2001) 0.77
Disorders of iron metabolism. N Engl J Med (2000) 0.77
Cellular pharmacologic strategies for overcoming drug resistance: potential applications to regional therapy. Eur J Surg Suppl (1991) 0.77
Stimulation of cis-diamminedichloroplatinum(II) accumulation by modulation of passive permeability with genistein: an altered response in accumulation-defective resistant cells. Clin Cancer Res (1996) 0.77
Drug accumulation and DNA platination in cells exposed to aquated cisplatin species. Cancer Lett (1994) 0.77
Renal transplantation in Wiskott-Aldrich syndrome. Transplantation (1993) 0.77
Breast cancer: incidence, mortality, and early detection in Louisiana, 1988-1997. J La State Med Soc (2001) 0.77
Renal transplantation in a patient with loin pain hematuria syndrome. Clin Nephrol (2006) 0.77
Increase in the ATP signal after treatment with cisplatin in two different cell lines studied by 31P NMR spectroscopy. Biochem Biophys Res Commun (1992) 0.76
Lipoprotein glomerulopathy: a new cause of nephrotic syndrome after renal transplantation. Implications for renal transplantation. Nephrol Dial Transplant (1999) 0.76
Ondansetron for symptomatic relief in terminal uraemia. Nephrol Dial Transplant (1995) 0.76
Antiphospholipid syndrome and systemic lupus erythematosus. Lancet (1993) 0.76
Preclinical and clinical experience with cisplatin resistance. Hematol Oncol Clin North Am (1995) 0.76
The care of patients undergoing hemodialysis. N Engl J Med (1999) 0.75
Oversensitive dipsticks? A minimalist take on urinalysis for microscopic haematuria. Int J Clin Pract (2008) 0.75
Asymptomatic haematuria. Nephrological screening is important. BMJ (2000) 0.75
Not yet time for a paradigm shift away from angiotensin inhibitors in chronic kidney disease, but due diligence required. Int J Clin Pract (2010) 0.75
Percutaneous endoscopic gastrostomy feeding. BMJ (1992) 0.75
Outcome of renal transplantation in Wiskott-Aldrich syndrome. Nephrol Dial Transplant (1998) 0.75
Considerations for toxicology studies of respiratory drug products. Regul Toxicol Pharmacol (1997) 0.75
Diarrhoea as a side effect of digoxin. BMJ (1990) 0.75
Centoxin: the full story of its withdrawal. Br J Hosp Med (1993) 0.75
Immunosuppression in renal transplantation. This meta-analysis has little relevance to current practice. BMJ (1999) 0.75
Cervical myxofibrosarcoma in a renal allograft recipient treated with murine anti-CD3 monoclonal antibody therapy. Nephrol Dial Transplant (1998) 0.75
Risk of pneumonia after hospital treatment for pneumonia. Lancet (1992) 0.75
Heart failure. Lancet (1998) 0.75
Palliative care for patients with terminal renal failure. Lancet (1995) 0.75
Anti-glomerular basement membrane antibody-mediated nephritis: when not to treat. Nephrol Dial Transplant (1999) 0.75
Successful pregnancy in cystinosis. JAMA (1994) 0.75
Disposition and metabolism of N,N-dimethyldaunorubicin and N,N-dimethyladriamycin in rabbits and mice. Drug Metab Dispos (1981) 0.75
Qualitative analysis of trimethylsilylated daunosamine and N-alkylated analogs by gas chromatography--mass spectrometry. Anal Biochem (1982) 0.75
Growth inhibition by thymidine of leukemic HL-60 and normal human myeloid progenitor cells. Cancer Res (1981) 0.75
Evidence for increased synthesis of complement C4 in the renal epithelium of rats with passive Heymann nephritis. J Am Soc Nephrol (1997) 0.75
The pharmacology of intraperitoneally administered bleomycin. J Clin Oncol (1987) 0.75
Disposition and metabolism of adriamycin octanoylhydrazone (NSC 233853) in mice and rabbits. Drug Metab Dispos (1981) 0.75
Cellular resistance to platinating agents in ovarian carcinoma. Prog Clin Biol Res (1986) 0.75
Aviator's cancer. Lancet (1968) 0.75
Louisiana Tumor Registry: new developments and activities. J La State Med Soc (1999) 0.75
Intravascular haemolysis and interstitial nephritis in association with ciprofloxacin. Nephron (1999) 0.75
Post-transplantation lymphoproliferative disorder: an unusual presentation in a patient receiving tacrolimus. Nephrol Dial Transplant (2000) 0.75
Advanced stage at diagnosis: an explanation for higher than expected cancer death rates in Louisiana? J La State Med Soc (1994) 0.75
Comparison of the pharmacokinetics of ultrafilterable cisplatin species detectable by derivatization with diethyldithiocarbamate or atomic absorption spectroscopy. Eur J Cancer (1990) 0.75
Reversed-phase high-performance liquid chromatography analysis of 6-thioguanine applicable to pharmacologic studies in humans. J Chromatogr (1982) 0.75
The effects of terbium on the accumulation of cisplatin in human ovarian cancer cells. Biochim Biophys Acta (1995) 0.75
Rhesus immunization after renal transplantation. Transplantation (1996) 0.75
The effects of terbium on the cellular accumulation of cisplatin in MDA-MB-231 human breast tumor cells. Cancer Chemother Pharmacol (1997) 0.75
Purification and characterization of aclacinomycin A and its metabolites from human urine. Drug Metab Dispos (1983) 0.75
Superoxide radical reactions with anthracycline antibiotics. Biochem Pharmacol (1985) 0.75